Fundacion Ars Medica | San Salvador de Jujuy, Argentina

Research site

(Unclaimed)

Location

Coronel Puch 497, San Salvador de Jujuy, Jujuy, Argentina

Site insights

Top conditions

Top treatments

Pembrolizumab

M7824

Abemaciclib

Sacituzumab

LY2835219

Cisplatin

Bemarituzumab

Bintrafusp Alfa

LY3009806

LY2801653

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

7 of 8 total trials

Locations recently updated

A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)

Researchers are looking for new ways to treat types of breast cancer that are both:* High-risk, which means the cancer may have a higher chance of ge...

Enrolling

Triple Negative Breast Neoplasms

Breast Neoplasms

Drug: Carboplatin

Drug: Cyclophosphamide

Locations recently updated

A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202)

The primary objectives are to compare progression-free survival (PFS) and overall survival (OS) in participants who receive sotorasib with platinum d...

Enrolling

Non-Small Cell Lung Cancer (NSCLC)

Drug: Sotorasib

Drug: Pembrolizumab

Locations recently updated

A Study of Abemaciclib (LY2835219) Plus Tamoxifen or Abemaciclib Alone in Women With Metastatic Breast Cancer (Next MONARCH 1)

The main purpose of this study is to evaluate the safety and efficacy of abemaciclib plus tamoxifen or abemaciclib alone in women with previously tre...

Active, not recruiting

Metastatic Breast Cancer

Drug: Abemaciclib

Drug: Prophylactic Loperamide

A Study of Ramucirumab (LY3009806) or Merestinib (LY2801653) in Advanced or Metastatic Biliary Tract Cancer

The main purpose of this study is to evaluate the efficacy and safety of ramucirumab or merestinib or placebo plus cisplatin and gemcitabine in parti...

Active, not recruiting

Advanced Cancer

Metastatic Cancer

Drug: Ramucirumab

Drug: Gemcitabine

A Study to Compare ABP 234 and Keytruda® (Pembrolizumab) in Participants With Advanced or Metastatic Non-squamous Non-Small Cell Lung Cancer

The primary objective of this study is to compare the efficacy of ABP 234 with the pembrolizumab reference product (Keytruda®).

Active, not recruiting

Advanced or Metastatic Non-squamous Non-Small Cell Lung Cancer

Drug: ABP 234

Drug: Pembrolizumab (EU)

Bemarituzumab Plus Chemotherapy and Nivolumab Versus Chemotherapy and Nivolumab for FGFR2b Overexpressed Untreated Advanced Gastric and Gastroesophageal Junction Cancer. (FORTITUDE-102)

The main objective of Part 1 is to evaluate the safety and tolerability of bemarituzumab plus 5-fluorouracil, leucovorin, and oxaliplatin (mFOLFOX6)...

Active, not recruiting

Gastric Cancer

Gastroesophageal Junction Adenocarcinoma

Other: Placebo

Drug: Nivolumab

Locations recently updated